Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Time Posted：2022-09-14 21:49
Recently, the COVID-19 epidemic has continued to rebound, and the pressure to prevent infection from mutant strains remains high. It is noteworthy that Healthgen and its subsidiary, Lizhu Group, recently announced that "Recombinant Novel Coronavirus Fusion Protein Vaccine" (hereinafter referred to as "Likang V-01"), jointly developed by Lizhu Monoclonal Antibody and the Institute of Biophysics, Chinese Academy of Sciences, has been approved for inclusion in the emergency use of sequential booster immunization for novel coronavirus prevention and control, following suggestions from the National Health Commission and review by the National Medical Products Administration. This provides a more flexible and scientific choice for susceptible populations and is of great significance for curbing the spread of the epidemic. Industry insiders believe that the approval of Likang V-01 for emergency use in sequential booster immunization will further enhance Healthgen's core competitiveness. If it is subsequently procured and used on a large scale by relevant national departments, it will have a positive impact on its performance, and the company's value will be re-recognized.
Time Posted：2022-09-13 21:31
Under the continuous influence of policies such as centralized procurement and dynamic medical insurance negotiations, the landscape of China's pharmaceutical industry is being restructured through accelerated innovation and transformation. Against the backdrop of the industry's rapid reshuffling, a large number of pharmaceutical companies are being eliminated or 'cleared out' due to their inability to adapt to the needs of the new era. Conversely, pharmaceutical companies with innovative spirits and a knack for seizing opportunities in the industry's transformation are becoming industry leaders through their comprehensive strength and continuous innovation.
The Vaccine "Newbie" and the Healthy Yuan's Gambit
Time Posted：2022-09-08 21:39
After more than two years of research and development and clinical trials, the Zhuhai Livzon recombinant protein COVID-19 vaccine V-01 has finally appeared on the list for emergency use in sequential booster immunization.
Time Posted：2022-09-08 19:12
On September 6, the China Enterprise Confederation and the China Entrepreneur Association held a press conference in Beijing to release the "2022 Top 500 Chinese Enterprises" list and its analysis report, as well as a series of lists such as the "2022 Top 500 Chinese Manufacturing Enterprises". In this selection, Joincare Pharmaceutical Group Industry Co., Ltd. was ranked among the "2022 Top 500 Chinese Manufacturing Enterprises".
Time Posted：2022-09-03 22:50
Following a recommendation from the National Health Commission, the National Medical Products Administration organized an argument and agreed to include it in the emergency use of sequential strengthening immunity for the prevention and control of novel coronavirus.
Time Posted：2022-08-26 14:12
Public Notice
Time Posted：2022-08-15 15:48
A high-quality entrepreneurial and innovative environment is attractive to cities and fosters creativity for businesses. On August 8, the Zhejiang University School of Management and Shenzhen Press Group's Deep New Communication Think Tank jointly released the "2022 China Listed Companies Innovation Index Report." The report shows that Shenzhen, known as the "City of Innovation," has 34 companies on the top 500 list of the innovation index, including Health Yuan, Mindray Medical, and Geillis, ranking third among all cities, after Shanghai and Beijing.
Time Posted：2022-08-11 19:34
On the evening of August 10, Joincare Pharmaceutical Group Industry Co., Ltd. (Joincare, 600380.SH) released its 2022 semi-annual performance report. The report shows that Joincare achieved operating revenue of 8.565 billion yuan in the first half of 2022, a year-on-year increase of 9.31%; net profit attributable to shareholders of the listed company reached 801 million yuan, a year-on-year increase of 16.57%, with basic earnings per share of 0.4235 yuan.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.